# Vitamin D regulates COVID-19 associated severity by suppressing the NLRP3 inflammasome pathway

**Authors:** Bariaa Khalil, Narjes Saheb Sharif-Askari, Shirin Hafezi, Fatemeh Saheb Sharif-Askari, Fatme Al Anouti, Qutayba Hamid, Rabih Halwani

PMC · DOI: 10.1371/journal.pone.0302818 · PLOS ONE · 2024-05-15

## TL;DR

Vitamin D3 reduces severe inflammation in COVID-19 by suppressing the NLRP3 inflammasome pathway, potentially improving patient outcomes.

## Contribution

Demonstrates that VitD3 downregulates the NLRP3 inflammasome pathway in severe COVID-19 patients.

## Key findings

- VitD3 treatment significantly lowers NLRP3, cleaved caspase-1, ASC, and IL-1β gene and protein expression.
- Reduced inflammasome activation correlates with lower disease severity and enhanced type I IFN pathway.
- VitD3 shows anti-inflammatory effects during SARS-CoV-2 infection, suggesting potential as a low-cost treatment.

## Abstract

The role of vitamin D3 (VitD3) in modulating innate and adaptive immunity has been reported in different disease contexts. Since the start of the coronavirus disease-2019 (COVID-19) pandemic, the role of VitD3 has been highlighted in many correlational and observational studies. However, the exact mechanisms of action are not well identified. One of the mechanisms via which VitD3 modulates innate immunity is by regulating the NLRP3-inflammasome pathway, being a main underlying cause of SARS-CoV-2-induced hyperinflammation.

Blood specimens of severe COVID-19 patients with or without VitD3 treatment were collected during their stay in the intensive care unit and patients were followed up for 29 days. qPCR, western blot, and ELISA were done to investigate the mechanism of action of VitD3 on the NLRP3 inflammasome activation.

We here report the ability of VitD3 to downregulate the NLRP3-inflammsome pathway in severe COVID-19 patients. Lower inflammasome pathway activation was observed with significantly lower gene and protein expression of NLRP3, cleaved caspase-1, ASC and IL-1β among severe COVID-19 patients treated with VitD3. The reduction of the inflammasome pathway was associated with a reduction in disease severity markers and enhancement of type I IFN pathway.

Our data reveals an important anti-inflammatory effect of VitD3 during SARS-CoV-2 infection. Further investigations are warranted to better characterize the ability of VitD3 to control disease pathogenesis and prevent progression to severe states. This will allow for a more efficient use of a low cost and accessible treatment like VitD3.

## Linked entities

- **Genes:** NLRP3 (NLR family pyrin domain containing 3) [NCBI Gene 114548], Caspase1 (caspase-1) [NCBI Gene 692604], STS (steroid sulfatase) [NCBI Gene 412], IL1B (interleukin 1 beta) [NCBI Gene 3553]
- **Chemicals:** vitamin D3 (PubChem CID 5280795)
- **Diseases:** coronavirus disease-2019 (MONDO:0100096)

## Full-text entities

- **Genes:** PYCARD (PYD and CARD domain containing) [NCBI Gene 29108] {aka ASC, CARD5, TMS, TMS-1, TMS1}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, CASP1 (caspase 1) [NCBI Gene 834] {aka ICE, IL1BC, P45}, NLRP3 (NLR family pyrin domain containing 3) [NCBI Gene 114548] {aka AGTAVPRL, AII, AVP, C1orf7, CIAS1, CLR1.1}
- **Diseases:** inflammatory (MESH:D007249), COVID-19 (MESH:D000086382)
- **Species:** Severe acute respiratory syndrome coronavirus 2 (no rank) [taxon 2697049], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11095707/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11095707/full.md

## References

75 references — full list in the complete paper: https://tomesphere.com/paper/PMC11095707/full.md

---
Source: https://tomesphere.com/paper/PMC11095707